SMARCB1-Deficient Malignancies
1 clinical trials · Condition
◉ Watch SMARCB1-Deficient Malignancies
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (NCT06444880) | M.D. Anderson Cancer Center | 2024-10-09 |
Track SMARCB1-Deficient Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.